Efficacy of bupropion alone and in combination with nicotine gum.
In this double-blind, placebo-controlled smoking cessation treatment study, 608 participants were randomly assigned to receive active bupropion and active 4-mg gum (AA, n = 228), active bupropion and placebo gum (AP, n = 224), or placebo bupropion and placebo gum (PP, n = 156). Relative to the PP group, the AA and AP groups were each significantly more likely to be abstinent at 1 week, end of treatment, and 6 months but not at 12 months postquit. After the first week postquit there were no differences in abstinence rates between the AA and AP groups. We found no significant individual difference variables that moderated outcome beyond 1 week postquit.
Piper
Megan E
ME
University of Wisconsin School of Medicine and Public Health, Center for Tobacco Research and Intervention, Madison, WI 53711, USA. mep@ctri.medicine.wisc.edu
Federman
E Belle
EB
McCarthy
Danielle E
DE
Bolt
Daniel M
DM
Smith
Stevens S
SS
Fiore
Michael C
MC
Baker
Timothy B
TB
D000279:Administration, Cutaneous; D000328:Adult; D016642:Bupropion / Q000008:administration & dosage*; D002638:Chewing Gum; D003692:Delayed-Action Preparations; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000008:administration & dosage*; D010349:Patient Compliance; D000074606:Smoking Prevention; D014029:Tobacco Use Disorder / Q000188:drug therapy*; D016896:Treatment Outcome
D002638:Chewing Gum; D003692:Delayed-Action Preparations; D018765:Dopamine Uptake Inhibitors; D016642:Bupropion; D009538:Nicotine